Reports Q2 revenue $98.61M, consensus $90.79M. Joseph Capper, MiMedx (MDXG) CEO, commented, “We are proud to report on the Company’s outstanding second quarter 2025 results, which included top-line net sales growth of 13%. This performance was driven by balanced, double-digit year-over-year growth from our Wound and Surgical franchises to produce our highest ever quarterly net sales. Additionally, our continued expense discipline and operational efficiency contributed to a record Adjusted EBITDA and a increase of $12 million for an ending cash balance of $119 million. Our commercial momentum gives us confidence that we will now be in a position to deliver net sales growth in the low double-digits for the full year.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDXG:
- MiMedx announces strategic collaboration with Vaporox
- Video: Why Organogenesis And MiMedx Are Sinking Today
- MiMedx comments on proposed Medicare reimbursement rule changes
- Northland sees ‘key positive’ for MiMedx in CMS rule proposal
- Organogenesis selloff on CMS proposal ‘may be incorrect,’ says BTIG